Adicet Bio (ACET) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Key advantages of gamma delta CAR T cells in autoimmune diseases

• Gamma delta T cells offer consistent pharmacokinetics and B-cell depletion similar to alpha beta T cells, with lower risk of CRS and ICANS.

• Off-the-shelf manufacturing enables consistent potency, rapid availability, and addresses autologous manufacturing challenges.

• Superior tissue tropism allows targeting of organs affected by autoimmune diseases, such as kidney and lung.

• Safety profile is enhanced by reduced cytokine secretion and minimal risk of CAR T cell malignancy.

• Efficacy endpoints focus on B-cell depletion, autoantibody reduction, and disease activity scores.

Clinical development and trial design updates

• Enrollment for lupus nephritis, SLE, systemic sclerosis, and ANCA vasculitis planned for 2024, with clinical updates expected in 2024 and 2025.

• Initial data expected in the first half of next year, with possible earlier updates.

• Trial arms use a starting dose of 3E8, with endpoints including cellular kinetics, B-cell dynamics, and disease activity.

• Allogeneic approach ensures consistent product quality and overcomes autologous manufacturing challenges.

• Projected cash runway extends into the second half of 2026, supporting ongoing and planned clinical activities.

Advantages and differentiation in oncology pipeline

• Gamma delta T cells' tissue tropism and innate anti-tumor activity address key challenges in solid tumors.

• ADI-270, a CD70-targeted CAR T, uses CD27 for potent tumor engagement at low antigen density.

• CD27 provides additional costimulatory signals and may enhance persistence and efficacy.

• TGF-beta dominant negative receptor incorporated to counteract tumor immunosuppression.

• ADI-270 demonstrates superior cytotoxicity in low or absent CD70 environments compared to alpha beta CAR Ts.